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Abstract
Berberine (BRB) is commonly used in herbal medicine, but its mechanisms of action are poorly understood. In the
present study, we tested BRB in steatohepatitis induced by a methionine- and choline-deficient (MCD) diet, in acute
acetaminophen intoxication and in cultured murine macrophages. BRB markedly improved parameters of liver injury
and necroinflammation induced by the MCD diet, although increased mortality was observed by mechanisms
independent of bacterial infections or plasma levels of BRB. The MCD diet induced up-regulation of all components
of the NLRP3 (NACHT, LRR and PYD domain-containing protein 3) inflammasome, and increased hepatic levels of
mature IL-1β (interleukin 1β). All of these parameters were significantly reduced in mice treated with BRB. In mice
administered an acetaminophen overdose, a model dependent on inflammasome activation, BRB reduced mortality
and ALT (alanine aminotransferase) elevation, and limited the expression of inflammasome components. In vitro,
LPS (lipopolysaccharide)-induced activation of NLRP3 inflammasome in RAW264.7 murine macrophages was
markedly decreased by pre-incubation with BRB. BRB significantly limited the activation of the purinergic receptor
P2X7, involved in the late phases of inflammasome activation. Upon P2X7 knockdown, the ability of BRB to block
LPS-induced secretion of IL-1β was lost. These data indicate that administration of BRB ameliorates inflammation
and injury in two unrelated murine models of liver damage. We demonstrate for the first time that BRB interferes
with activation of the NLRP3 inflammasome pathway in vivo and in vitro, through a mechanism based on
interference with activation of P2X7, a purinergic receptor involved in inflammasome activation.
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INTRODUCTION
Non-alcoholic fatty liver disease, including NASH (non-
alcoholic steatohepatitis), is the most prevalent form of liver
disease in Western countries [1]. More importantly, a diagnosis
of NASH is associated with a higher risk of overall mortality
and of liver-related mortality, indicating that strategies to prevent
Abbreviations: ALT, alanine aminotransferase; APAP, acetaminophen; ASC, apoptosis-associated speck-like protein containing a caspase recruitment domain; BRB, berberine; CCL2,
CC chemokine ligand 2; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HDS, herbal or dietary supplements; IκBα, inhibitor of NF-κB α; IL, interleukin; i.p., intraperitoneally; LPS,
lipopolysaccharide; MCD, methionine- and choline-deficient; NASH, non-alcoholic steatohepatitis; NF-κB, nuclear factor κB; NLRP3, NACHT, LRR and PYD domain-containing protein 3;
RT, reverse transcription; TGF-β, transforming growth factor β; TNFα, tumour necrosis factor α.
Correspondence: Dr Fabio Marra (email fabio.marra@unifi.it).
progression of liver injury are needed [2]. However, no clearly
effective pharmacological therapies are approved for this con-
dition, and patients often self-administer herbal or dietary sup-
plements (HDS) that are advertised to be beneficial to this and
possibly other hepatic abnormalities. Although the use of HDS
is increasing dramatically, diffusion of these compounds is not
accompanied by an adequate knowledge of their mechanism of
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action, and this limits the possible development of purified active
molecules and/or their recommendation on a larger scale [3].
Berberine (BRB) is the main alkaloid component of several
plants used for centuries in traditional Chinese and Ayurvedic
medicine, including Berberis aquifolium or Coptis chinensis [4].
This chemical is a quaternary ammonium salt that belongs to the
protoberberine group of isoquinoline alkaloids, and can be found
in the root and bark of herbs, such as goldenseal, berberis and
Chinese goldthread [5]. Alone or in combination with other HDS,
BRB extracts are one of the top selling products in the U.S.A. and
in Europe. The success of BRB started along with reports of its
multiple pharmacological and biochemical properties, including
cholesterol-lowering [6], anti-diabetic [7], antioxidant [8], hep-
atoprotective [9], anti-inflammatory [10], antibacterial [11] and
anti-tumoral activities [12]. Although many different mechan-
isms of action have been hypothesized, only a few of them have
been validated with appropriate experimental techniques.
Inflammation plays a relevant role in the pathogenesis of dif-
ferent forms of acute and chronic liver injury, including NASH
[13]. In the present study, we show that BRB exerts potent anti-
inflammatory actions in two unrelated in vivo models of liver
injury, and report for the first time that BRB inhibits the activa-
tion of the NLRP3 (NACHT, LRR and PYD domain-containing




Unless indicated otherwise, all chemicals were purchased from
Sigma Chemical Co.
Animals and experimental protocol
Wild-type C57BL/6 mice were obtained from Charles River
Laboratories. In all experiments, 6–8-week-old male mice were
used. At least six mice for control conditions and eight mice for
experimental conditions were analysed. All animals were treated
with humane care and experimental protocols performed accord-
ing to established guidelines (Guide for the Care and Use of
Laboratory Animals, NIH publication No. 86-23) after approval
by the local regulatory authorities.
Steatohepatitis model
Mice were fed on a methionine- and choline-deficient (MCD)
diet (Laboratori Dottori Piccioni) for 28 days, as described pre-
viously [14]. A methionine- and choline-sufficient control diet
was supplemented with choline chloride (2 g/kg diet) and D,L-
methionine (3 g/kg diet). BRB (5 mg/kg) or its vehicle (10 %
DMSO/saline) were injected i.p. (intraperitoneally) every day for
28 days. Mice had unrestricted access to food and water. Body
weight was recorded weekly. At the end of the study protocol,
mice were anaesthetized and killed by exsanguination. Blood was
collected and centrifuged, and serum was stored for further ana-
lysis. Livers were rapidly dissected out, weighed, snap-frozen in
liquid nitrogen and kept at 80 ◦C for RNA and protein extrac-
tion. A portion of the liver was immediately fixed in formalin for
histological analysis.
Acetaminophen (APAP) intoxication
Mice were starved 12–15 h before the treatment with APAP. The
drug (500 mg/kg) or its vehicle (saline) were administered i.p.
BRB (1 or 5 mg/kg) or its vehicle (10 % DMSO in saline) were
injected i.p., 24 and 2 h before APAP treatment. In one experi-
ment, mice were observed for 72 h to record animals survival. In
a parallel experiment, mice were killed at different time points
(6 and 12 h), by exsanguination under anaesthesia. After collect-
ing blood, livers were excised. Samples obtained after 6 h were
freshly analysed for determination of glutathione (GSH), whereas
those at 12 h were snap-frozen in liquid nitrogen and kept at 80 ◦C
for DNA and protein extraction.
ALT (alanine aminotransferase) activity and
cholesterol levels
Blood samples were centrifuged at 1500 g for 10 min at 4 ◦C,
and serum was stored at −20 ◦C until analysis. Serum ALT activ-
ity was determined using Reflotron® Plus system (Roche Dia-
gnostics). Serum cholesterol was determined using a Dimension
Vista® system (Siemens Healthcare).
Liver histology
A portion of liver tissue was fixed by immersion in 10 % buffered
formalin (pH 7.4) for 24 h. The fixed tissue was dehydrated in
graded ethanol, paraffin-embedded and sectioned at a thickness of
4 μm. Haematoxylin/eosin staining was performed as described
previously [14]. Liver histology was evaluated by an experienced
hepatopathologist (S.M.) blinded to the type of treatment received
by the animals. Necroinflammation was graded focusing on zone
3 as 0 (absent), 1 (sparse or mild, focal), 2 (noticeable) and 3
(severe).
RNA isolation and quantitative PCR
Procedures for hepatic RNA isolation and quantitative real-time
PCR have been described in detail elsewhere [14]. GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) was used as house-
keeping gene. FAM (6-carboxyfluorescein)-labelled probes and
specific primers were obtained as Assays-on-Demand (Applied
Biosystems). Supplementary Table S1 presents a list of the
primers used. Relative gene expression was calculated as 2–CT
(CT = CT of the target gene−CT of GAPDH).
Measurement of serum BRB concentration by
LC–MS/MS analysis
Plasma samples were measured using a HPLC PerkinElmer
Series 200 micropump apparatus and chromatographed using
a 75 mm×2.0 mm internal diameter, 4 μm particle size 80 Å
(1Å = 0.1 nm) Synergi Polar-RP column (Phenomenex). Mobile
phase A consisted of water containing 3 % acetonitrile and 0.1 %
formic acid, and mobile phase B was acetonitrile containing 3 %
water and 0.1 % formic acid. An elution gradient was performed
from 5 to 90 % phase B in 12 min. B was held at 90 % for 3 min,
and then brought back to the starting value in 1 min. The equilib-
ration time before the next injection was 10 min. The eluate, at a
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flow rate of 200 μl/min, was directly introduced into the LC–MS
interface. The LC–MS/MS system consisted of a PerkinElmer
Sciex API 365 triple-quadrupole mass spectrometer (Thornhill)
equipped with a Turbo IonSpray Interface. The compounds were
ionized by positive-ion electrospray and detected using MRM
(multiple reaction monitoring). The needle and orifice voltage
were adjusted to 5.5 kV and 66 V respectively. The drying gas
flow rate and temperature were 7 l/min and 300 ◦C respectively.
The first and third quadrupole mass analysers were operated at
unit mass resolution. Fragmentation was accomplished with a
collision energy of 51 eV for BRB and 32 eV for internal stand-
ard (ranitidine). Nitrogen was used as the collision gas at a CGT
(collision gas thickness) of 2.6×1015 molecules·cm−2. The ion
transition monitored were m/z 336→292, 336→320 for BRB and
m/z 315→175 for ranitidine.
LPS (lipopolysaccharide)-stimulated RAW264.7
cells
RAW264.7 murine macrophages were kindly provided by Dr
Elisabetta Rovida (Dipartimento di Scienze Biomediche, Sper-
imentali e Cliniche “Mario Serio”, University of Florence,
Florence, Italy) and were cultured in DMEM (Dulbecco’s mod-
ified Eagle’s medium) containing 10 % (v/v) FBS, 100 units/ml
penicillin and 100 μg/ml streptomycin at 37 ◦C in 5 % CO2. After
plating in 12-well plates (500000 cells/well) cells were treated
with LPS (1 μg/ml) following or not BRB pre-treatment (20 μM)
2 h before LPS. Cells were collected 2 and 8 h after LPS for RNA
isolation. In other experiments, after 24 h the supernatants were
collected for protein assay.
Intracellular calcium measurement
RAW264.7 cells were incubated in a solution containing 150 mM
NaCl, 10 mM Hepes, 3 mM KCl, 2 mM CaCl2, 1 mM MgCl2 and
10 mM glucose (pH 7.3), at 37 ◦C for 30 min with the 5 μM cell-
permeant calcium dye Fluo-3 acetoxymethyl ester (Molecular
Probes). To facilitate Fluo-3 solubilization in aqueous medium,
1 mM pluronic F-127 was added (Molecular Probes). The dye
was allowed to de-esterify for 30 min at room temperature. Cov-
erslips containing Fluo-3-loaded cells were subsequently trans-
ferred to a continuously perfused microscope stage for imaging
where they were perfused for 10 min with Hepes solution before
performing calcium imaging recordings. Images were visualized
with a 20× Fluor objective and acquired every 2 s. Exposure time
was set to 200 ms and excitation was provided by a PE-1 system
(CoolLED) equipped with a 470 +− 30 nm LED. Fluo-3 fluores-
cence was recorded through a bandpass filter (535 +− 25 nm) with
a Photometrics Coolsnap HP Camera set at −20 ◦C. Fluorescence
intensity was measured using Imaging Workbench 6 software (In-
dec BioSystems) and expressed as the ratio of (F–F0)/F0, where
F0 is the baseline fluorescence intensity in cell bodies before
any treatment. All measurements were corrected for background
fluorescence. Increases in fluorescence ratio greater than 0.2 were
considered significant. Experiments were performed at room
temperature.
Gene silencing
Cultured RAW264.7 cells were serum-deprived and transfected
with non-targeting siRNA (siGENOME Non-Targeting siRNA
Pool, GE Dharmacon) or siRNA targeting murine P2X7 (siRNA-
Smart Pool, GE Dharmacon) using an Amaxa device, as described
previously [15]. After 48 h, cells were collected for analysis of
P2X7 expression by quantitative RT (reverse transcription)–PCR
or incubated with LPS or its vehicle, in the presence or absence
of BRB, for an additional 24 h.
IL-1β (interleukin 1β) assay
Liver tissues were lysed at 4 ◦C with lysis buffer (1 % Triton X-
100, 50 mmol/l Tris/HCl, pH 7.4, 150 mmol/l NaCl, 1 mmol/l
EDTA, 1 mmol/l sodium orthovanadate, 2 mmol/l PMSF and
1 mmol/l each of leupeptin and pepstatin) in a Polytron mixer.
Tissue extracts were centrifuged at 12 000 g for 10 min, and the
supernatant was used for mature IL-1β assay, as indicated by the
manufacturer (R&D Systems).
For experiments in RAW264.7 cells, media conditioned for
24 h in the presence of appropriate stimuli were frozen at −20 ◦C
and used for IL-1β assay. Data are expressed as pg/ml after
normalization of the amount of protein in each sample.
Western blot analysis
Isolation of total protein from RAW264.7 cells and subsequent
Western blot analysis was performed according to previously
published procedures [15].
Statistical analysis
Unless stated otherwise, data are expressed as means +− S.E.M.
Comparisons of different conditions was performed by Student’s t
test. Histological scores of inflammation were compared using the
Mann–Whitney U test. Survival curves were evaluated using the
Kaplan-Meier method. P values less than 0.05 were considered
significant.
RESULTS
BRB reduces necroinflammation in experimental
steatohepatitis
We first explored the effects of BRB on the development of
steatohepatitis induced by administration of a MCD diet for
4 weeks. In all mice administered the MCD diet, body weight was
markedly and significantly decreased (Table 1). The reduction in
liver weight was significantly less pronounced in mice receiving
BRB together with the MCD diet. No evident changes in the
general behaviour of mice was observed comparing animals re-
ceiving BRB or its vehicle. As is well established, this diet caused
a rapid and marked accumulation of fat in hepatocytes, with a pre-
dominant macrovesicular pattern, and an evident infiltration with
inflammatory cells, often detected in foci or surrounding groups
of hepatocytes with microvesicular steatosis, as lipogranulomas
[14]. Treatment with BRB did not modify the grade of steatosis,
whereas it resulted in a marked improvement of inflammation
associated with the MCD diet, as was evident when analysing
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Table 1 Effects of berberine on liver and body weight in mice
fed on a methionine- and choline-deficient diet for 4 weeks
Data are means +− S.D. *P < 0.05 compared with CD+vehicle.∧P < 0.05 compared with MCD+vehicle. #P = 0.056 compared with
MCD+vehicle.
Body weight Liver weight Liver/body
Treatment (g) (g) weight ratio (%)
CD+vehicle 25.4 +− 1.4 1.17 +− 0.18 4.6 +− 0.8
CD+BRB 23.0 +− 1.2 1.06 +− 0.13 4.6 +− 0.8
MCD+vehicle 15.8 +− 1.1* 0.61 +− 0.09* 3.9 +− 0.7*
MCD+BRB 16.8 +− 1.3* 0.76 +− 0.11*∧ 4.5 +− 0.6#
the histological pictures (Figure 1A). These effects were asso-
ciated with a marked and significant reduction in ALT levels in
comparison with mice receiving only the MCD diet (Figure 1B).
When the histological scores of necroinflammation were evalu-
ated, the marked and significant increase associated with MCD
diet-induced steatohepatitis was virtually abolished by treatment
with BRB, resulting in scores similar to those measured in mice
administered the control diet (Figure 1C). In addition, BRB re-
duced apoptosis induced by the MCD diet (Supplementary Figure
S1). These data indicate that BRB treatment induces a marked
reduction of necroinflammation in mice administered with the
MCD diet. Of note, no significant effects on any of these para-
meters or on hepatic histology were observed when mice were
treated with BRB alone.
Steatohepatitis triggers a multicellular response, involving
liver resident and infiltrating cells, resulting in reprogramming
of different genes to co-ordinate a complex inflammatory re-
sponse [13]. To assess the effects of BRB on these factors, we
evaluated intrahepatic expression of genes involved in liver in-
flammation and repair. A 3-fold increase in the expression of
CD11B , a marker of leucocyte activation, was observed in mice
receiving the MCD diet, whereas a significant reduction was
found in animals treated with BRB (Figure 2A). A similar be-
haviour was observed when expression of TNFα (tumour nec-
rosis factor α), which is pivotally involved in the pathogenesis
of NASH, was analysed (Figure 2B). Inflammation in steatohep-
atitis is characterized by a polarization of macrophages towards
a pro-inflammatory, M1-type, phenotype, which contributes to
disease progression and fibrogenesis [16]. These aspects were
recapitulated by the significant increase in expression of CCL2
(CC chemokine ligand 2) and NOS2 (nitric oxide synthase 2), the
inducible form of nitric oxide synthase (Figures 2C and 2D), in
mice receiving the MCD diet. BRB administration significantly
reduced the expression levels of these genes. Chronic liver injury,
including that caused by NASH, leads to progressive fibrosis and
ultimately cirrhosis. A fibrogenic phenotype is not apparent after
4 weeks on the MCD diet, but activation of fibrogenic factors such
as TGF-β (transforming growth factor β) or type I procollagen
(Figures 2E and 2F) was already evident at the gene expression
level. BRB treatment reduced TGF-β expression by approxim-
ately 50 % in comparison with untreated animals. Similarly, the
marked and significant increase in type I procollagen gene ex-
pression was reduced in mice receiving the herbal supplement
together with the MCD diet. Collectively, these data indicate that
Figure 1 Berberine administration reduces injury and inflamma-
tion in a murine model of steatohepatitis
Male C57BL/6 mice were administered a diet deficient in methionine
and choline (MCD) or a control diet (CD) for 4 weeks, together with
BRB (5 mg/kg/day) or its vehicle (VEH). (A) Haematoxylin and eosin
staining of liver tissue indicates normal liver tissue in mice receiving the
control diet irrespective of co-administration of vehicle or BRB. Animals
on the MCD diet developed a typical picture of steatohepatitis together
with marked infiltration of inflammatory cells (arrows). The inflammatory
aspects were markedly decreased in mice administered the MCD diet
and receiving BRB. Scale bar, 100 μm. (B) At the time of killing, blood
was drawn and ALT levels were measured in the different groups of
mice, as indicated. (C) The hepatic inflammatory score was determined
as indicated in the Experimental section. Results are individual scores
for mice analysed in the different groups. *P < 0.05 compared with
CD+VEH; ∧P < 0.05 compared with MCD+VEH.
BRB ameliorates the inflammatory phenotype and limits expres-
sion of fibrogenic genes associated with experimental steatohep-
atitis induced by a MCD diet.
Administration of BRB together with the MCD diet
increases animal mortality
To establish whether BRB could effectively limit deposition of
fibrotic tissue after prolonged exposure to the MCD diet, we in-
tended to analyse a group of animals for 8 weeks, a time point
where a typical pericentral ‘chickenwire’ fibrosis is observed.
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Figure 2 The induction of genes involved in hepatic inflammation and repair during steatohepatitis is reduced by BRB
administration
Male C57BL/6 mice were administered a diet deficient in methionine and choline (MCD) or a control diet (CD) for 4 weeks,
together with BRB (5 mg/kg per day) or its vehicle (VEH). At the end of the experiment, RNA was isolated from liver
tissue and expression of CD11B (A), TNFα (B), CCL2 (C), NOS2 (D), TGF-β (E) and α1 procollagen I (F) was measured by
quantitative RT–PCR as described in the Experimental section. *P < 0.05 compared with CD+VEH; ∧P < 0.05 compared
with MCD+VEH.
Unfortunately, we observed that animals treated with BRB when
administered the MCD diet showed an excess of mortality during
the first weeks of study compared with those receiving vehicle
(Figure 3A). At the 4-week time point, more than half of the mice
on BRB and the MCD diet died, whereas this number was neg-
ligible in those receiving the MCD diet alone. Of note, no mice
receiving BRB died while on the control diet (Figure 3A), thus
ruling out a possible toxic effect of the BRB preparation used.
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Figure 3 Increased mortality of mice exposed to MCD together with berberine
Male C57BL/6 mice were administered a diet deficient in methionine and choline (MCD) or a control diet (CD) for 4 weeks,
together with BRB (5 mg/kg per day) or its vehicle (VEH). (A) Survival of mice in the different experimental groups as
indicated as a percentage of the starting number. *P < 0.05 compared with all other groups. (B) At the time of killing,
blood was drawn and levels of total cholesterol were measured in the different groups of mice, as indicated. *P < 0.05
compared with CD+VEH. (C) The plasma levels of BRB were measured by MS in mice receiving the control diet (CD) or the
MCD diet. (D) Mice treated with CD and vehicle (CD+VEH), MCD and vehicle (MCD+VEH) or MCD and BRB (MCD+BRB)
with or without amoxicillin/clavulanate, a broad-spectrum antibiotic (MCD+BRB+Atb). Survival of mice in the different
experimental groups is indicated as percentage of the starting number. *P < 0.05 compared with MCD+VEH.
At necroptic examination, the animals that died upon admin-
istration of MCD and BRB showed bilateral effusions in the
lungs, associated with inflammatory cell infiltration. To establish
whether bacterial infections could be responsible for the death of
this group of animals, we repeated the experiment administering
a broad-spectrum antibiotic treatment, with the hypothesis that
increased susceptibility to bacterial infection might contribute
to the negative outcome. However, co-administration of amox-
icillin/clavulanate did not significantly affect mice survival (Fig-
ure 3D).
BRB has been reported to lower serum cholesterol levels, an
effect which is also observed in animals administered a MCD diet
[17]. To exclude the possibility that excessively low cholesterol
levels had a negative effect on animal survival, we measured
serum cholesterol levels in different groups of mice. Whereas
the MCD diet induced a significant decrease in serum cho-
lesterol levels (Figure 3B), further decreases induced by co-
administration of BRB were only modest and non-significant,
indicating that mortality could not be explained by dramatically
low cholesterol levels in the MCD plus BRB group. We finally
considered that an altered BRB metabolism in mice receiving the
MCD diet could result in elevated, and potentially toxic, levels of
BRB. We set up an MS-based method to measure BRB levels in
serum, and compared the levels of this compound in mice receiv-
ing BRB together with the two types of diet (Figure 3C). However,
BRB levels were comparable in the two groups of animals, show-
ing that excessive circulating levels of BRB are not related to the
increased mortality observed in the MCD diet group. Consider-
ing the amelioration of steatohepatitis in mice receiving BRB,
these results indicate that association of BRB with a MCD diet
increases mortality of mice by a mechanism unrelated to the liver,
and independent of bacterial infections, low cholesterol levels or
excessive circulating BRB.
BRB reduces activation of the NLRP3
inflammasome pathway in two independent models
Accumulating evidence indicates the possible role of the inflam-
masome pathway in the regulation of liver damage and repair
induced by different conditions, including steatohepatitis. We
evaluated whether the remarkable decrease in the inflammatory
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response in mice receiving BRB was associated with changes in
activation of the inflammasome pathway and/or in the expres-
sion of its individual components. As reported previously [18],
intrahepatic expression of IL-1β, a potent pro-inflammatory cy-
tokine regulated by inflammasome activation, was significantly
increased in mice administered a MCD diet for 4 weeks (Fig-
ure 4A). Of note, co-treatment with BRB caused a marked and
significant reduction in IL-1β gene expression, which returned
to levels comparable with those of control mice. A similar be-
haviour was observed with expression of single components of
the inflammasome cascade, such as caspase 1, NLRP3, ASC
(apoptosis-associated speck-like protein containing a caspase re-
cruitment domain), and pannexin 1, a pore associated with the
purinergic P2X7 receptor was analysed (Figures 4B–4E). Be-
cause regulation of mRNA levels is not necessarily associated
with changes in the final multimolecular complex or in its activ-
ity, we measured the levels of mature IL-1β in the livers of mice
subjected to the different treatments. IL-1β was significantly in-
creased by the MCD diet, and this increase was no longer evid-
ent in animals receiving BRB. Together, these data indicate that
BRB interferes with the assembly of the inflammasome pathway
induced by experimental steatohepatitis.
To provide further in vivo evidence for the modulation of the
inflammasome pathways by BRB, we tested its effects in mice
with APAP-induced hepatotoxicity, where liver damage has been
previously shown to be dependent on inflammasome activation
[19]. Pre-treatment of mice with two different doses of BRB
(1 mg·kg−1 and 5 mg·kg−1) markedly and significantly reduced
the mortality caused by APAP overdose (Figure 5A). Accord-
ingly, the marked elevation in ALT levels induced by APAP was
significantly reduced by BRB, confirming the protective effects
observed on animal mortality (Figure 5B). These effects were
associated with a significant reduction in the expression of genes
related to the inflammasome pathway, specifically those encod-
ing caspase 1 and IL-1β (Figures 5C and 5D). To rule out the
possibility that the effects of BRB were related to modifications
of APAP metabolism, we measured the intrahepatic levels of
glutathione, as a reliable indicator of the accumulation of N-
acetyl-p-benzoquinone imine, the metabolite of APAP respons-
ible for the formation of adducts and for hepatocellular damage.
The decrease in glutathione levels induced by APAP was not sig-
nificantly modified by BRB, thus ruling out possible effects on
APAP metabolism. These data indicate that BRB administration
results in a reduced activation of the inflammasome pathway in
two unrelated murine models of liver injury.
BRB blocks inflammasome assembly and activation
in cultured murine macrophages
Because BRB is a potent anti-inflammatory agent, in vivo exper-
iments do not allow to establish whether reduced inflammasome
activation is a factor contributing to reduced inflammation, or
merely a consequence of a reduced recruitment of inflammatory
cells dependent on other mechanisms [20]. To clarify this critical
issue, we assessed the effects of BRB in cultured murine macro-
phages exposed to LPS. LPS determined a marked induction of
mRNA encoding inflammasome components, including IL-1β,
NLRP3 or ASC (Figures 6A–6C), and all of these effects were
significantly inhibited by BRB pre-treatment. More importantly,
BRB inhibited by approximately 60 % LPS-stimulated secretion
of mature IL-1β in the culture medium (Figure 6F). Activation of
NF-κB (nuclear factor κB) contributes to the early transcription
of genes encoding inflammasome components [21], and BRB
has been found to suppress the inflammatory response by
inhibiting NF-κB activation in many tissues [22,23]. To verify
whether modulation of inflammasome activation by BRB was
dependent on an interaction with NF-κB, we assessed activation
of this pathway by measuring the protein levels of IκBα
(inhibitor of NF-κB α) in LPS-treated cells (Figure 6E). As
expected, LPS reduced the levels of IκBα, the regulatory protein
which prevents NF-κB migration to the nucleus and activation
of pro-inflammatory genes. Pre-treatment of RAW264.7 cells
with BRB did not inhibit NF-κB activation, as indicated by
levels of IκBα comparable with those of cells receiving vehicle,
following LPS treatment. To provide additional evidence for the
involvement of NF-κB-independent pathway(s) in the regulation
of inflammasome by BRB, we measured the effects of BRB
on LPS-induced expression of TNFα, a cytokine regulated by
NF-κB activation in an inflammasome-independent fashion.
The 10-fold increase in TNFα mRNA levels, induced by LPS
in RAW264.7 macrophages, was not significantly modified by
BRB treatment (Figure 6D). Collectively, these results indicate
that BRB inhibits activation of NRLP3 inflammasome with an
action independent of NF-κB.
BRB interferes with activation of the purinergic
receptor P2X7
Activation of the purinergic receptor P2X7 is pivotal to provide
a ‘second signal’ which leads to inflammasome assembly and
activation [24]. We hypothesized that BRB could interfere with
binding of damage-associated molecular patterns, such as ATP,
to P2X7, thus limiting the inflammatory response associated
with liver damage. When RAW264.7 murine macrophages were
exposed to benzyl-ATP, a selective P2X7 receptor agonist, an
evident calcium transient was observed, indicating activation of
downstream signalling eventually contributing to inflammasome
activation (Figure 7A). Pre-treatment with BRB markedly and
significantly attenuated benzyl-ATP-induced calcium efflux, in-
dicating an inhibitory interaction with P2X7-mediated signalling
(Figures 7A and 7B). To provide evidence that P2X7 is a major
target of BRB, we evaluated the effects of genetic knockdown of
P2X7 on the ability of BRB to block IL-1β secretion. After P2X7
knockdown, LPS was still able to significantly up-regulate IL-
1β secretion in RAW264.7 cells, although less efficiently than
in cells transfected with non-targeting siRNA. In contrast, the
ability of BRB to block LPS-induced IL-1β secretion was lost in
cells silenced for P2X7, indicating the critical role of this receptor
in mediating the inhibitory effects of BRB on inflammasome ac-
tivation in this model.
DISCUSSION
The use of HDS for the treatment of different disorders, including
liver diseases, has expanded tremendously, and data from 2007
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Figure 4 Activation of the inflammasome system associated with experimental steatohepatitis is modulated by
berberine
Male C57BL/6 mice were administered a diet deficient in methionine and choline (MCD) or a control diet (CD) for 4 weeks,
together with BRB (5 mg/kg/day) or its vehicle (VEH). (A–E) At the end of the experiment, RNA was isolated from liver
tissue and expression of IL-1β (A), caspase 1 (B), NLRP3 (C), ASC (D) and pannexin-1 (E) was measured by quantitative
RT–PCR as described in the Experimental section. (F) Hepatic levels of mature IL-1β were tested in the different groups
using ELISA, as described in the Experimental section. *P < 0.05 compared with CD+VEH; ∧P < 0.05 compared with
MCD+VEH.
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Figure 5 Berberine protects mice from acetaminophen (APAP) toxicity and limits inflammasome activation
Mice were administered a single dose of APAP (500 mg/kg i.p.) or saline (SAL), together with 1 or 5 mg/kg BRB, as
indicated, or its vehicle (VEH). (A) Survival of mice in the different experimental groups indicated as percentage of the
starting number. *P < 0.05 compared with SAL+VEH; ∧P < 0.05 compared with APAP+VEH; §P = 0.058 compared with
APAP+VEH). (B) At the time of killing, blood was drawn and ALT levels measured in the different groups of mice, as
indicated. (C and D) RNA was isolated from liver tissue and expression of IL-1β (C) or caspase 1 (D) was measured
by quantitative RT–PCR as described in the Experimental section. (E) Intrahepatic levels of glutathione were measured
in control mice and in mice receiving acetaminophen with or without BRB, 6 h after administration of APAP. *P < 0.05
compared with control; ∧P < 0.05 compared with APAP+VEH.
indicate that as many as 17 % of Americans have used at least once
a natural product at least once (https://nccih.nih.gov/research/
statistics/NHIS/2012/key-findings; accessed July 2015). Al-
though undoubtedly some natural compounds show efficacy for
the treatment of liver disease, information on their mechanisms
of action is still scarce, and lack of these lines of evidence limits
the eventual development of novel drugs based on HDS. BRB
is found in tea and in several over-the-counter HDS, and ranks
among the top ten most commonly used herbal supplements in
children in the U.S.A. [25]. In the present study, we demonstrate
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Figure 6 Berberine modulates inflammasome activation in cultured murine macrophages
RAW264.7 cells were incubated with LPS or PBS in the presence of BRB (20 μM) or its vehicle (VEH) for 2 h. (A–D) RNA
was isolated from liver tissue and expression of IL-1β (A), NLRP3 (B), ASC (C) or TNF-α (D) was measured by quantitative
RT–PCR as described in the Experimental section. (E) Cells were lysed and expression of IκBα or of the housekeeping
gene β -actin was analysed by Western blotting (upper panel). The lower panel shows quantification of Western blot signals
in three independent experiments (means +− S.E.M.). (F) Levels of mature IL-1β were measured in the supernatants of
the different experimental conditions using ELISA, as described in the Experimental section. *P < 0.05 compared with
PBS+VEH; ∧P < 0.05 compared with LPS+VEH.
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Figure 7 Berberine interferes with intracellular signalling generated by activation of the purinergic receptor P2X7
(A) RAW264.7 cells were loaded with Fluo-3 to measure intracellular calcium levels. Representative traces of cells
exposed to benzyl-ATP without (black trace) or with (red trace) 40 μM BRB pre-incubation. Time is indicated on the
x-axis, fluorescence intensity variations expressed as (F−F0)/F0 are on the y-axis. (B) Maximal intracellular calcium peak
recorded after benzyl-ATP application in the two different experimental conditions (n = 37 and 18 respectively). The highest
peak amplitude was measured within 2 min of challenging cells with benzyl-ATP, whereas baseline values were obtained
by averaging calcium levels recorded 1 min before benzyl-ATP administration. *P < 0.0001 compared with control. (C)
RAW264.7 cells were transfected with non-targeting siRNA or siRNA targeting the purinergic receptor P2X7, as indicated.
After 48 h, expression levels of P2X7 were assessed by quantitative RT–PCR (means +− S.E.M., n = 4). (D) RAW264.7 cells
silenced as described in (C) were incubated with LPS in the presence or absence of 20 μM BRB for 24 h, as indicated.
Levels of mature IL-1β were measured in the supernatants of the different experimental conditions using ELISA, as
described in the Experimental section. *P < 0.05 compared with control. **P < 0.05 compared with LPS without BRB.
Results are means +− S.E.M. (n = 4).
for the first time that the NLRP3 inflammasome is a target of
the action of BRB in vivo and in vitro, providing evidence for a
novel mechanism underlying the potent anti-inflammatory action
of this compound.
Starting from available data suggesting a hepatoprotective
role of BRB in liver disease [9], we first investigated the effects
of this compound in mice administered a MCD diet, a widely
accepted model of experimental steatohepatitis. In fact, NASH
represents a condition where no clearly effective treatments are
yet available, and, on the other hand, patients with metabolic ab-
normalities are very likely to take different HDS. Administration
of BRB to mice on a MCD diet resulted in a striking reduction of
several parameters of intrahepatic inflammation and in a marked
amelioration of liver histology. Of note, these changes were also
associated with a reduced activation of fibrogenic genes, which
eventually lead to tissue scarring. It should be pointed out that,
surprisingly, the amelioration in the hepatic phenotype was asso-
ciated with increased animal mortality. This precluded us from
extending the investigation to longer time points to assess the
possible effects of BRB on fibrosis in this model. Although the
negative impact of BRB on survival was apparently independ-
ently of the actions on the liver, it should be considered that only
a fraction of animals initially administered MCD diet and BRB
were available for final analysis. Therefore future experiments
with different administration schedules of BRB and/or different
models of steatohepatitis are warranted.
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We extensively investigated why co-exposure to a MCD diet
and BRB results in such a negative effect on survival, which was
independent of the effects on the liver and of the BRB preparation
itself, which did not exhibit any toxic effects when administered
alone. It has been reported that, in HepG2 cells, BRB is able to
induce apoptotic and autophagic cell death [26], but in the present
study, BRB actually reduced apoptosis induced in the liver by the
MCD diet. We ruled out an accumulation of BRB by measuring
its circulating levels through a novel MS-based assay method.
Nonetheless, it should be considered that in these experiments
plasma BRB concentrations were approximately 6-fold higher
than those measured when administered to patients with non-
alcoholic fatty liver disease [27]. Thus the possibility that higher
plasma levels and/or the route of administration (i.p. compared
with oral) may have had an impact on toxicity cannot be ruled
out. We also excluded the possibility that excessively low choles-
terol levels had been reached in animals treated with the MCD
diet and BRB, in the light of the cholesterol-lowering properties
of this compound. As some of the mice dying while on BRB
and the MCD diet had signs suggesting pneumonia at necropsy,
we repeated the experiment administering antibacterial agents to
mice, but no effects on mortality were observed. Although the
ultimate reason for this unforeseen effect remains unclear, it is
possible that in the setting of cachexia associated with the MCD
diet, the dramatic reduction in antimicrobial defence caused by
BRB favoured opportunistic infections not responsive to common
antibacterial agents. An alternative, but not mutually exclusive,
hypothesis is that the neurotoxic effects of BRB reported in some
experimental settings [28] were maximized by the MCD diet by
mechanisms independent of plasma levels of BRB, for example
via generation of metabolites.
The dramatic anti-inflammatory effect of BRB in the MCD
dietary model prompted us to explore its possible interference
with the inflammasome system. Inflammasomes are a group of
multimeric protein complexes triggered by a range of stimuli gen-
erated during infection, tissue damage or metabolic imbalance
[29]. Upon formation of the protein complex, the inflammasome
activates caspase 1, which proteolytically cleaves the precursors
of the pro-inflammatory cytokines IL-1β and IL-18. In addition,
inflammasome activation causes a rapid pro-inflammatory form
of cell death called pyroptosis, which is relevant in the process
of so-called ‘sterile inflammation’, observed in different condi-
tions of liver injury including NASH [21]. This is confirmed by
recent data by Wree et al. [30], who demonstrated that mice ex-
pressing a constitutively active form of NLRP3 under control of
the endogenous NLPR3 promoter develop extensive liver inflam-
mation, hepatocyte pyroptosis and liver fibrosis. In mice with
steatohepatitis induced by a MCD diet, administration of BRB
clearly modulated inflammasome activation, as indicated by sig-
nificantly reduced gene expression of its components and, more
importantly, by a marked reduction of the intrahepatic accumu-
lation of mature IL-1β. Moreover, BRB reduced inflammasome
activation and tissue damage also in mice with APAP-induced
liver damage, a model of injury which has been closely associ-
ated with inflammasome activation [19], where a lower dose of
BRB was even more effective. Thus experiments in two independ-
ent models of ‘sterile inflammation’ indicate that modulation of
the NLRP3 inflammasome may be considered as a previously
unrecognized action of BRB, possibly contributing to its anti-
inflammatory effects.
The anti-inflammatory action of BRB has been described
previously, and has been attributed to modulation of different
pathways, including NF-κB [22,23]. We then conducted in vitro
experiments using murine macrophages to establish whether the
reduced activation of NLRP3 inflammasome was a direct effect
of BRB or rather the result of inflammation dampening depend-
ent on other pathways. The observation that BRB is capable of
potently reducing activation of all inflammasome components in
isolated cells exposed to LPS strongly suggests that this pathway
is a bona fide target of BRB. On the other hand, no significant
effects of BRB on the activation of NF-κB were found, indicating
that, although this pathway is indispensable for the early phases
of NLRP3 inflammasome activation (signal 1 [31]), it does not
represent the major target of BRB in this context.
For these reasons, we focused on the molecular mechanisms
that are implicated in the later stages of inflammasome activ-
ation, where a second signal, possibly generated by damaged
cells, results in changes in calcium and potassium fluxes, leading
to the final assembly of the multimolecular inflammasome com-
plex [32]. Among the molecules implicated in the generation of
this signal 2, we focused on ATP and its cognate purinergic re-
ceptor P2X7, on the basis of the structural characteristics of BRB,
which, as an alkaloid, could possibly interfere with this receptor
family [33]. Remarkably, the intracellular calcium flux induced
by exposure of murine macrophages to an ATP analogue was
markedly dampened by pre-treatment with BRB, indicating that
interference with signal 2 of inflammasome assembly represents
a novel target implicated in the action of BRB in this setting.
These data are in agreement with those reported previously using
compounds structurally similar to BRB, which displayed non-
competitive inhibition of the P2X7 receptor [34,35].
Additional future work will be required to explore additional
aspects highlighted by the present study. Henao-Mejia et al. [36]
have reported that genetic deletion of inflammasome components
favours NASH through interaction with the intestinal microbiota
[36]. It will be interesting to establish whether BRB adminis-
tration results in changes in gut ecology, including possible ac-
tions on the microbiota itself and/or on the immunity or barrier
function of the intestine. On more clinical grounds, the observa-
tion that BRB increases animal mortality when associated with a
MCD diet suggests that possible toxic effects of this supplement
should be carefully reassessed in humans, as several HDS con-
tain BRB. Although the MCD model reproduces the histological
changes associated with NASH, severe deficiency of methionine
and choline is infrequent in humans. However, choline deficiency
has been reported in alcoholics and in obese patients, who, on
the basis of our data, might potentially be at higher risk of BRB
toxicity.
In conclusion, administration of BRB reduces inflammation
and modulates the activation of the inflammasome pathway in a
model of experimental steatohepatitis and after acetaminophen
intoxication in mice. These effects are associated with block-
ade of calcium flux induced by the purinergic receptor P2X7,
identifying a novel molecular mechanism by which BRB
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limits inflammation. The present study highlights the relevance
of a better understanding of the pharmacological mechanisms
of commonly used HDS, which could be useful for the develop-
ment of novel therapeutic tools and for comprehension of toxicity
associated with some of these compounds.
CLINICAL PERSPECTIVES
• The use of herbal and dietary supplements for the treatment
of liver diseases is growing, but information on the molecular
mechanisms underlying their actions is limited.
• We show that berberine, one of the more widely used herbal
medicines, limits the activation of the NLRP3 inflammasome,
a pathway involved in the pathogenesis of inflammation and in-
jury in many liver diseases. The action of berberine is mediated
by interference with the purinergic receptor P2X7. Berberine
decreased the survival of mice treated with a methionine- and
choline-deficient diet, suggesting the need to reassess possible
toxic effects if this compound in humans.
• Understanding how berberine acts is critical for the develop-
ment of novel therapeutic tools, possibly exploiting the iden-
tification of the role of P2X7 in this context.
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